Schneeweiss, A. (2019). Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer - lack of association between activating AKT mutation and AKT inhibition-derived efficacy. Cancers, 11(12), . https://doi.org/10.3390/cancers11121987
Chicago-Zitierstil (17. Ausg.)Schneeweiss, Andreas. "Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer - Lack of Association Between Activating AKT Mutation and AKT Inhibition-derived Efficacy." Cancers 11, no. 12 (2019). https://doi.org/10.3390/cancers11121987.
MLA-Zitierstil (9. Ausg.)Schneeweiss, Andreas. "Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer - Lack of Association Between Activating AKT Mutation and AKT Inhibition-derived Efficacy." Cancers, vol. 11, no. 12, 2019, https://doi.org/10.3390/cancers11121987.